Fmr LLC Purchases 9,115 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

FMR LLC grew its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 0.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,292,881 shares of the company's stock after purchasing an additional 9,115 shares during the quarter. FMR LLC owned about 14.93% of Krystal Biotech worth $781,433,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in KRYS. Summit Trail Advisors LLC bought a new stake in shares of Krystal Biotech during the 3rd quarter valued at $1,893,000. Swiss National Bank raised its stake in Krystal Biotech by 8.0% in the third quarter. Swiss National Bank now owns 39,100 shares of the company's stock valued at $7,117,000 after purchasing an additional 2,900 shares in the last quarter. Sei Investments Co. lifted its position in Krystal Biotech by 18.9% during the second quarter. Sei Investments Co. now owns 40,115 shares of the company's stock worth $7,367,000 after purchasing an additional 6,363 shares during the period. Shaker Investments LLC OH acquired a new stake in Krystal Biotech during the third quarter worth about $532,000. Finally, Amalgamated Bank increased its holdings in Krystal Biotech by 937.9% in the 2nd quarter. Amalgamated Bank now owns 7,577 shares of the company's stock valued at $1,391,000 after buying an additional 6,847 shares during the period. Institutional investors own 86.29% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on KRYS shares. HC Wainwright reaffirmed a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a report on Tuesday, November 5th. Evercore ISI lifted their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a research report on Monday, August 12th. William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, Stifel Nicolaus increased their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech has an average rating of "Buy" and a consensus target price of $202.29.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 14.10% of the company's stock.

Krystal Biotech Trading Up 0.2 %

Shares of KRYS stock traded up $0.39 on Thursday, hitting $196.91. 139,869 shares of the stock were exchanged, compared to its average volume of 325,090. The firm's 50 day moving average is $180.23 and its two-hundred day moving average is $183.28. Krystal Biotech, Inc. has a one year low of $99.00 and a one year high of $219.34. The firm has a market capitalization of $5.66 billion, a PE ratio of 111.25 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm's revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.67) EPS. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).